Jennifer Kim

Swayampakula Ramakanth

Benjamin Burnett

Brian Cheng

Jason Butler

Lut Ming Cheng

- Precigen (PGEN) announced long-term follow-up data for **PAPZIMEOS™ (zopapogene imadenovec-drba)**, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), which received full approval in **August 2025**.  **[1356090_20251013NY95670:0]** 
- The data, as of September 19, 2025, showed that **83% (15 out of 18)** of complete responders maintained ongoing complete responses with a median follow-up of **36 months**.  **[1356090_20251013NY95670:0]** 
- A significant **reduction in surgeries** compared to pre-treatment was observed in **86% of patients in Year 1, 91% in Year 2, and 95% in Year 3**, with **no new safety events** reported during long-term follow-up.  **[1356090_20251013NY95670:0]**

PRECIGEN (PGEN)